ATE306270T1 - Verwendung von fulvestrant in der behandlung von resistentem brustkrebs - Google Patents

Verwendung von fulvestrant in der behandlung von resistentem brustkrebs

Info

Publication number: ATE306270T1
Authority: AT; Austria
Prior art keywords: fulvestrant; treatment; breast cancer; resistant breast; resistant
Prior art date: 2000-04-05

Application number

AT01917289T

Other languages

English (en)

Inventor

Beat Thurlimann

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-05

Filing date

2001-04-02

Publication date

2005-10-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9889101&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE306270(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-04-02 Application filed filed Critical

2005-10-15 Application granted granted Critical

2005-10-15 Publication of ATE306270T1 publication Critical patent/ATE306270T1/de

Links

206010006187 Breast cancer Diseases 0.000 title abstract 2
208000026310 Breast neoplasm Diseases 0.000 title abstract 2
VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 title abstract 2
229960002258 fulvestrant Drugs 0.000 title abstract 2
229940095743 selective estrogen receptor modulator Drugs 0.000 abstract 2
239000000333 selective estrogen receptor modulator Substances 0.000 abstract 2
229940122815 Aromatase inhibitor Drugs 0.000 abstract 1
239000003886 aromatase inhibitor Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT01917289T 2000-04-05 2001-04-02 Verwendung von fulvestrant in der behandlung von resistentem brustkrebs ATE306270T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0008172.9A GB0008172D0 (en)	2000-04-05	2000-04-05	Therapy
PCT/GB2001/001500 WO2001074366A1 (en)	2000-04-05	2001-04-02	Use of fulvestrant in the treatment of resistant breast cancer

Publications (1)

Publication Number	Publication Date
ATE306270T1 true ATE306270T1 (de)	2005-10-15

Family

ID=9889101

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01917289T ATE306270T1 (de)	2000-04-05	2001-04-02	Verwendung von fulvestrant in der behandlung von resistentem brustkrebs

Country Status (28)

Country	Link
US (2)	US20030158166A1 (de)
EP (2)	EP1272195B1 (de)
JP (1)	JP2003528919A (de)
KR (1)	KR100757764B1 (de)
CN (1)	CN1431905A (de)
AT (1)	ATE306270T1 (de)
AU (2)	AU4437201A (de)
BR (1)	BR0109789A (de)
CA (1)	CA2403608A1 (de)
CH (1)	CH1272195H1 (de)
CZ (1)	CZ303096B6 (de)
DE (1)	DE60113975T2 (de)
DK (1)	DK1272195T3 (de)
EE (1)	EE05026B1 (de)
ES (1)	ES2248300T3 (de)
GB (1)	GB0008172D0 (de)
HU (1)	HU230064B1 (de)
IL (2)	IL151932A0 (de)
IS (1)	IS2869B (de)
MX (1)	MXPA02009744A (de)
NO (1)	NO329949B1 (de)
NZ (1)	NZ539603A (de)
PL (1)	PL201175B1 (de)
RU (1)	RU2265438C2 (de)
SK (1)	SK287779B6 (de)
UA (1)	UA80388C2 (de)
WO (1)	WO2001074366A1 (de)
ZA (1)	ZA200207538B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0116620D0 (en) *	2001-07-07	2001-08-29	Astrazeneca Ab	Formulation
EP1406662A1 (de) *	2001-07-07	2004-04-14	AstraZeneca AB	Pharmazeutische zubereitung für die intramuskuläre verabreichung von fulvestrant
EP1623713A1 (de) *	2004-07-09	2006-02-08	Proskelia SAS	Kombinationen von reinen Antiestrogen und Aromataseinhibitoren
US8557863B2 (en) *	2005-09-27	2013-10-15	Robert Benson Aylor	Suppression and prevention of tumors
WO2007062093A2 (en) *	2005-11-22	2007-05-31	Incyte Corporation	Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
US7910108B2 (en) *	2006-06-05	2011-03-22	Incyte Corporation	Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
RU2013154048A (ru) *	2011-05-09	2015-06-20	Юниверсити Оф Вирджиния Пэтент Фаундейшн	Композиции и способы лечения рака
CA2836831C (en)	2011-05-20	2015-06-02	Capital, Business Y Gestion De Finanzas S.L.	Pharmaceutical composition
EP3092027A4 (de) *	2014-01-10	2017-09-06	Atossa Genetics Inc.	Transpapilläre verfahren und zusammensetzungen zur diagnose und behandlung von brusterkrankungen
US9421264B2 (en) *	2014-03-28	2016-08-23	Duke University	Method of treating cancer using selective estrogen receptor modulators
EP3681491A4 (de)	2017-09-11	2021-06-30	Atossa Therapeutics, Inc.	Verfahren zur herstellung und verwendung von endoxifen
JP7384903B2 (ja) *	2018-05-24	2023-11-21	ケーアイファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー	フルベストラントのプロドラッグ
WO2021003433A1 (en)	2019-07-03	2021-01-07	Atossa Therapeutics, Inc.	Sustained release compositions of endoxifen
CA3210276A1 (en) *	2020-02-29	2021-09-02	Frances E. Carr	Use of thyromimetics for the treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6362371B1 (en) *	1998-06-08	2002-03-26	Advanced Medicine, Inc.	β2- adrenergic receptor agonists
US6465445B1 (en) *	1998-06-11	2002-10-15	Endorecherche, Inc.	Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors

2000
- 2000-04-05 GB GBGB0008172.9A patent/GB0008172D0/en not_active Ceased
2001
- 2001-02-04 UA UA2002118734A patent/UA80388C2/uk unknown
- 2001-04-02 WO PCT/GB2001/001500 patent/WO2001074366A1/en not_active Ceased
- 2001-04-02 AU AU4437201A patent/AU4437201A/xx active Pending
- 2001-04-02 DK DK01917289T patent/DK1272195T3/da active
- 2001-04-02 US US10/240,656 patent/US20030158166A1/en not_active Abandoned
- 2001-04-02 ES ES01917289T patent/ES2248300T3/es not_active Expired - Lifetime
- 2001-04-02 JP JP2001572110A patent/JP2003528919A/ja active Pending
- 2001-04-02 HU HU0300339A patent/HU230064B1/hu unknown
- 2001-04-02 RU RU2002129355/14A patent/RU2265438C2/ru active
- 2001-04-02 KR KR1020027013366A patent/KR100757764B1/ko not_active Expired - Lifetime
- 2001-04-02 IL IL15193201A patent/IL151932A0/xx active IP Right Grant
- 2001-04-02 CN CN01810539A patent/CN1431905A/zh active Pending
- 2001-04-02 DE DE60113975T patent/DE60113975T2/de not_active Expired - Lifetime
- 2001-04-02 CA CA002403608A patent/CA2403608A1/en not_active Abandoned
- 2001-04-02 CZ CZ20023309A patent/CZ303096B6/cs not_active IP Right Cessation
- 2001-04-02 BR BR0109789-0A patent/BR0109789A/pt not_active Application Discontinuation
- 2001-04-02 AU AU2001244372A patent/AU2001244372B2/en not_active Expired
- 2001-04-02 CH CH01917289T patent/CH1272195H1/de unknown
- 2001-04-02 SK SK1429-2002A patent/SK287779B6/sk not_active IP Right Cessation
- 2001-04-02 EP EP01917289A patent/EP1272195B1/de not_active Expired - Lifetime
- 2001-04-02 NZ NZ539603A patent/NZ539603A/en not_active IP Right Cessation
- 2001-04-02 PL PL357936A patent/PL201175B1/pl unknown
- 2001-04-02 EP EP05007561A patent/EP1586323A1/de not_active Withdrawn
- 2001-04-02 AT AT01917289T patent/ATE306270T1/de active
- 2001-04-02 MX MXPA02009744A patent/MXPA02009744A/es active IP Right Grant
- 2001-04-02 EE EEP200200574A patent/EE05026B1/xx unknown
2002
- 2002-09-19 ZA ZA200207538A patent/ZA200207538B/en unknown
- 2002-09-25 IL IL151932A patent/IL151932A/en unknown
- 2002-10-01 IS IS6576A patent/IS2869B/is unknown
- 2002-10-02 NO NO20024735A patent/NO329949B1/no not_active IP Right Cessation
2010
- 2010-09-30 US US12/895,369 patent/US20110183949A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NO329949B1 (no)	2011-01-31
ZA200207538B (en)	2003-12-19
KR20030007501A (ko)	2003-01-23
AU2001244372B2 (en)	2006-02-16
NO20024735D0 (no)	2002-10-02
US20110183949A1 (en)	2011-07-28
IL151932A (en)	2007-07-04
EE05026B1 (et)	2008-06-16
CN1431905A (zh)	2003-07-23
PL357936A1 (en)	2004-08-09
EP1272195B1 (de)	2005-10-12
AU4437201A (en)	2001-10-15
IS6576A (is)	2002-10-01
KR100757764B1 (ko)	2007-09-12
GB0008172D0 (en)	2000-05-24
HUP0300339A2 (hu)	2003-06-28
WO2001074366A1 (en)	2001-10-11
DE60113975D1 (de)	2006-02-23
CZ20023309A3 (cs)	2003-02-12
PL201175B1 (pl)	2009-03-31
BR0109789A (pt)	2003-01-21
ES2248300T3 (es)	2006-03-16
DE60113975T2 (de)	2006-06-22
HUP0300339A3 (en)	2009-01-28
SK14292002A3 (sk)	2003-08-05
HK1051498A1 (en)	2003-08-08
JP2003528919A (ja)	2003-09-30
NZ539603A (en)	2008-02-29
HU230064B1 (hu)	2015-06-29
EP1272195A1 (de)	2003-01-08
CA2403608A1 (en)	2001-10-11
SK287779B6 (sk)	2011-09-05
DK1272195T3 (da)	2006-01-16
MXPA02009744A (es)	2004-02-26
US20030158166A1 (en)	2003-08-21
EP1586323A1 (de)	2005-10-19
IL151932A0 (en)	2003-04-10
CH1272195H1 (de)	2019-10-15
RU2265438C2 (ru)	2005-12-10
UA80388C2 (en)	2007-09-25
CZ303096B6 (cs)	2012-04-04
NO20024735L (no)	2002-11-27
IS2869B (is)	2014-03-15
EE200200574A (et)	2004-04-15

Legal Events

Date

Code

Title

Description

2006-05-15

UEP

Publication of translation of european patent specification

Ref document number: 1272195

Country of ref document: EP

Publication	Publication Date	Title
DE60037394D1 (de)	2008-01-24	VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
DE60113975D1 (de)	2006-02-23	Verwendung von fulvestrant in der behandlung von resistentem brustkrebs
ATE305306T1 (de)	2005-10-15	Reboxetin zur behandlung von peripheren neuropathien
BRPI0407305A (pt)	2006-02-07	Ligantes do receptor de canabinóides e seus usos
DE60138129D1 (de)	2009-05-07	Apparat zur behandlung von zähnen
ATE313326T1 (de)	2006-01-15	VERWENDUNG VON CABERGOLIN ZUR BEHANDLUNG VON ßRESTLESS LEGS SYNDROMß
ATE300597T1 (de)	2005-08-15	Behandlung von geweben
ATE308997T1 (de)	2005-11-15	Mittel zur behandlung von erkrankungen der speiseröhre
DE69936335D1 (de)	2007-08-02	Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
ATE295735T1 (de)	2005-06-15	Verwendung von interleukin-6 antagonisten zur behandlung von oestrogen-abhängigen krebs
DE69921852D1 (de)	2004-12-16	Kombinationstherapie enthaltend bestrahlung und einen cox-2 hemmer in der behandlung von neoplasie
DE69911210D1 (de)	2003-10-16	Verwendung von piperin und derivate davon zur behandlung von hautpigmentierungstörungen und hautkrebs
DE60023816D1 (de)	2005-12-15	Verwendung von Lycopin in Zusammensetzungen zur Behandlung von Hautalterungs-Erscheinungen
ATE346614T1 (de)	2006-12-15	Vaginale zusammensetzung enthaltend lidocaine zur behandlung von gebärmutterrhythmusstörung
DE60324431D1 (de)	2008-12-11	Derivate des 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazols als antagonisten des gonadotropin freisetzenden hormons (gnrh) zur anwendung in de behandlung von geschlechtshormonellen erkrankungen, wie prostata- oder gebahrmutterkrebs
DE60030861D1 (de)	2006-11-02	Verwendung von escitalopram zur Behandlung von generalisierten Angstzuständen
DE50114605D1 (de)	2009-02-05	No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE69931487D1 (de)	2006-06-29	Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
DE69924284D1 (de)	2005-04-21	Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten
DE60229047D1 (de)	2008-11-06	Einzeldosis aromatase hemmer zur behandlung von unfruchtbarkeit
DE60109594D1 (de)	2005-04-28	R-eliprodil zur behandlung von glaucoma
EP1646385A4 (de)	2008-01-02	Verwendung von benzothiopenen zur behandlung und prävention von prostatakrebs
ATE291434T1 (de)	2005-04-15	Verwendung von angiotensin zur behandlung von krebsmetastasierung
DE69926996D1 (de)	2005-10-06	Verwendung von riluzol zur behandlung der retinalischemie
ATE288263T1 (de)	2005-02-15	Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis)